Abstract
The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Current Drug Discovery Technologies
Title: High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions
Volume: 5 Issue: 3
Author(s): Pierre Colas
Affiliation:
Keywords: High-throughput screening, protein interactions, drug discovery, two-hybrid
Abstract: The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify smallmolecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.
Export Options
About this article
Cite this article as:
Colas Pierre, High-Throughput Screening Assays to Discover Small-Molecule Inhibitors of Protein Interactions, Current Drug Discovery Technologies 2008; 5 (3) . https://dx.doi.org/10.2174/157016308785739875
DOI https://dx.doi.org/10.2174/157016308785739875 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery
Current Topics in Medicinal Chemistry The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging
Anti-Cancer Agents in Medicinal Chemistry Centrality Measures in Biological Networks
Current Bioinformatics Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued) The Crosstalk between Tissue Engineering and Pharmaceutical Biotechnology: Recent Advances and Future Directions
Current Pharmaceutical Biotechnology Combined <i>Curcuma longa</i> and <i>Cratoxylum formosum</i> Extracts Possess Anti-liver Cancer and Anti-HBV Activities in HepG2.2.15
Current Traditional Medicine A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues
Current Medicinal Chemistry Targeting the Viral Nucleocapsid Protein in Anti-HIV-1 Therapy
Mini-Reviews in Medicinal Chemistry Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Molecular Origin of Color Variation in Firefly (Beetle) Bioluminescence: A Chemical Basis for Biological Imaging
Current Topics in Medicinal Chemistry Supercritical Fluid Extraction of Bioactive Compounds from Botanic Matrices: Experimental Data, Process Parameters and Economic Evaluation
Recent Patents on Engineering Metabolomics and Its Practical Value in Pharmaceutical Industry
Current Drug Metabolism Bioactive Proteins and Peptides from Food Sources. Applications of Bioprocesses used in Isolation and Recovery
Current Pharmaceutical Design Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Unravelling the Antioxidant Potential, Alpha-Glucosidase Inhibitory Activity and Phenolic Composition of Dendrocalamus strictus Plantations Generated Biomass Waste (Leaves)
The Natural Products Journal A Fluorescent Anti-Cancer Agent, 3,6-bis(1-methyl-4-vinylpyridinium) Carbazole Diiodide, Stains G-Quadruplexes in Cells and Inhibits Tumor Growth
Current Topics in Medicinal Chemistry Microfluidic approaches to synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectral microscopy of living biosystems
Protein & Peptide Letters Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism